Prospective Collection of Samples for Urothelial Cancer of Bladder (ProCSUCaB)

ProCSUCaB (Prospective Collection of Samples for Urothelial Cancer of Bladder) is a monocentric, non-interventional, prospective registry that will recruit newly diagnosed intermediate- and high-risk NMIBC patients in a tertiary center in Flanders.

Study Overview

• Status: Not yet recruiting
• Conditions: Bladder Cancer

Detailed Description

ProCSUCaB (Prospective Collection of Samples for Urothelial Cancer of Bladder) is a monocentric, non-interventional, prospective registry that will recruit newly diagnosed intermediate- and high-risk NMIBC patients in a tertiary center in Flanders.

Clinical data and biosamples (blood, urine, and BC tissue) will be collected from each patient at the initial diagnosis before the surgery and will be stored at -80 °C at the BioBank UZ Leuven after proper processing according to the protocol. High-throughput multi-omics (genomics, epigenomics, transcriptomics, proteomics, lipidomics, metabolomics) and immunohistopathology analyses will be performed on these samples.

Patients of both sex and aged ≥18 years, with a signal of clinical diagnosis of BC (symptoms and/or imaging), are eligible to participate in this study. Patients, who give their informed consent to collect their biological materials prior to surgery, will be included in the study after the histopathological diagnosis of the TURBT specimen shows an intermediate- or high-risk NMIBC. Only the data of the patients with a TCC, with the allowance of any variant histopathological subtype, will be analyzed.

All patients will be treated and followed up with the standard of care based on the recommendations of the EAU Guidelines according to their risk groups. All follow-ups will be scheduled for 5 years as most of the recurrences or progressions occur during this period.

To comply with local privacy laws, all demographic and clinical data (for initial diagnosis and following recurrences and/or progressions) will be prospectively stored in a specific database, which is implemented into the hospital's electronic patient file system, and protected by firewalls [24]. All patients will receive a study identification number, and names (or any other identifying data) will be removed from the collected biosamples; therefore, all -omics and pathology laboratories will not know the identity and clinical data of the patients. The correspondence between the study identification numbers and patient names will be kept by only the urology department in a secured database.

Blood, urine and BC tissue samples will be collected at the initial diagnosis for every patient. Blood and urine will be collected by the nurses in the inpatient department in the morning prior to TURBT. After processing by the dedicated personnel, they will be sent to the BioBank UZ Leuven, which has continuously monitored and alarmed freezers, robotic handling, and storage system, and has implemented the Standard Pre-analytical Code (SPREC).

Blood collection: In the morning prior to TURBT (between 07:00-11:00 am), blood will be taken from the patients into five separate tubes (4x 10 mL EDTA tubes for genomics, epigenomics, transcriptomics, and proteomics; 1x 6 mL EDTA tube for lipidomics and metabolomics). Collection date and time will be recorded in the 'Urine/Blood Sampling Form' by the nurse. All blood tubes will be inverted gently 10 times after blood collection. All EDTA tubes will immediately be put in the refrigerator at +4°C in upright position until centrifugation. All blood samples will be centrifuged within 4 hours of collection, and centrifuge date and time will be recorded in the 'Blood Processing and Storage Form'. After processing all blood samples according to the specific protocol of each analysis, all plasma/pellet/whole blood samples in cryovials will be sent to the BioBank UZ Leuven to be stored at -80 °C, and the date and time of the sample acceptance will also be recorded.

Urine collection: A total of 230 mL of mid-stream urine will be collected into five tubes from the second urine in the morning (between 07:00-11:00 am) before TURBT. The patient should be well hydrated. Collection date and time will be recorded in the 'Urine/Blood Sampling Form' by the nurse. The urine samples will immediately be stored at +4 °C in the refrigerator and processed within 2 hours after collection, and centrifuge date and time will be recorded in the 'Urine Processing and Storage Form'. After processing all urine samples according to the specific protocol of each analysis, all samples in cryovials will be sent to the BioBank UZ Leuven to be stored at -80 °C, and the date and time of the sample acceptance will also be recorded.

Tissue collection: During TURBT, if the tumor is large enough (>10 mm in diameter), a big chip that includes the tumor stalk will be cut with the resectoscope. The sample will be put in a cryovial, and sent to the BioBank immediately thereafter. The date and time of collection and acceptance will be recorded in the 'Tissue Sampling and Storage Form'. Cryosection will be performed from frozen samples by a uropathologist before -omics analyses to check for presence and area of intermediate- and high-risk NMIBC. After the uropathologist's report, frozen samples will be dissected to take parts enriched in tumor cells. The histopathological diagnosis of the patients will be made according to the hematoxylin-eosin (HE) staining of the slides from the formalin-fixed paraffin-embedded (FFPE) blocks, which will determine the ultimate inclusion of the intermediate- and high-risk NMIBC patients.

• Study Type: Observational
• Enrollment (Anticipated): 630

Contacts and Locations

• Study Contact: Name: Murat Akand, MD, FEBU; Phone Number: +32 16 34 69 30; Email: murat.akand@uzleuven.be
• Study Contact Backup: Name: Tim Muilwijk, MD; Phone Number: +32 16 34 69 30; Email: tim.muilwijk@uzleuven.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients of both sex and aged ≥18 years, with a signal of clinical diagnosis of bladder cancer (symptoms and/or imaging), who are willing to participate in this registry and who give their informed consent to collect their clinical data and biological materials prior to surgery.

Description

Inclusion Criteria:

1. A signal of clinical diagnosis of bladder cancer (symptoms and/or imaging)
2. Giving informed consent to collect clinical data and biological materials prior to surgery
3. An approved pathological diagnosis of transitional cell carcinoma (TCC), with allowance of any variant histopathological subtype
4. An approved pathological diagnosis of non-muscle-invasive bladder cancer (NMIBC), with stages of carcinoma in situ (CIS), Ta (mucosa-confined) and T1 (submucosa infiltrating)

Exclusion Criteria:

1. Aged less than 18 years
2. Not giving or withdrawing informed consent
3. Tumor histopathological type other than TCC, such as adenocarcinoma, squamous cell carcinoma

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

NMIBC; Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer. No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines. The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comprehensive multi-layered molecular characterization	Comprehensive multi-layered molecular characterization of intermediate- and high-risk NMIBC patients at the genomics, epigenomics, transcriptomics, proteomics, lipidomics, metabolomics, and immunohistopathology levels for disease recurrence and progression	In two years after completion of recruitment of planned number of patients
Multi-biomarker panel for disease recurrence and progression	Identification of a multi-biomarker panel that integrates multidimensional and longitudinal data with harnessing the power of various -omics, systems biology approach, network analysis and predictive modeling for a better stratification of intermediate- and high-risk NMIBC patients into their risk of recurrence and progression	In two years after completion of recruitment of planned number of patients
Multi-biomarker panel for response to BCG treatment	Identification of a multi-biomarker panel for molecular characterization of a patient subgroup who receive BCG treatment, identification of the pathways relevant to BCG treatment response, and stratification of those patients according to their predicted BCG response	In two years after completion of recruitment of planned number of patients

Collaborators and Investigators

• Sponsor: Universitaire Ziekenhuizen KU Leuven
• Collaborators: KU Leuven; Hospital Clinic of Barcelona; MDx Health; Biomedical Research Foundation, Academy of Athens; HistoGeneX; Mosaiques Diagnostics and Therapeutics AG
• Investigators: Principal Investigator: Steven Joniau, MD, PhD, UZ Leuven; Principal Investigator: Frank Van Der Aa, MD, PhD, UZ Leuven

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): December 1, 2019
• Primary Completion (ANTICIPATED): December 1, 2024
• Study Completion (ANTICIPATED): December 1, 2029

Study Registration Dates

• First Submitted: November 15, 2019
• First Submitted That Met QC Criteria: November 15, 2019
• First Posted (ACTUAL): November 18, 2019

Study Record Updates

• Last Update Posted (ACTUAL): November 18, 2019
• Last Update Submitted That Met QC Criteria: November 15, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Keywords: Biomarker; Progression; Recurrence; Non-muscle-invasive bladder cancer; Registry; Prospective; Multi-omics
• Additional Relevant MeSH Terms: Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Urinary Bladder Diseases; Urinary Bladder Neoplasms
• Other Study ID Numbers: S59371

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Due to ethical restrictions, anonymized data are available upon request to the Steering Committee. Anonymized data and biosamples of the patients can be requested for conducting scientific studies. All requests will be evaluated by the Steering Committee.
• IPD Sharing Time Frame: After completion of data and biosample collection.
• IPD Sharing Access Criteria: Upon request to the Steering Committee, and after request evaluated by the Steering Committee.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No